Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Adrian Husillos Alonso, Manuel Carbonero García, Carmen González Enguita

Abstract

Metastatic renal cell carcinoma (mRCC) is a challenging disease. Despite the new targeted therapies, complete remissions occur only in 1%-3% of the cases, and the most effective first-line treatment drugs have reached a ceiling in overall survival (ranging from 9 to 49 mo). Metastasectomy remains to be the only curative option in most patients with mRCC. Prognostic nomograms have been recently published, so we have tools to classify patients in risk groups, allowing us to detect the cases with the higher risk of recurrence after metastasectomy. Although sparse, there is some evidence of effectiveness of neoadjuvant targeted therapy before metastasectomy; but with an increase in surgical complications due to the effects of these new drugs in tissue healing. We have aimed to answer the question: Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma? We have made a search in Pubmed database. As far as we know, evidence is low and it's based in case reports and small series of patients treated with adjuvant drugs after neoadjuvant therapy plus metastasectomy in cases of partial response to initial systemic treatment. Despite the limitations and high risk of bias, promising results and cases with long-term survival with this approach have been described. Two ongoing clinical trials may answer the question that concerns us.

Key words: Metastatic renal cell carcinoma; Targeted therapy; Metastasectomy; Surgery; Adjuvant treatment

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We have made a search in Pubmed database looking for evidence to support adjuvant systemic therapy after metastasectomy in metastatic renal cell carcinoma. As far as we know, evidence is low and it’s based in case reports and small series of patients. Despite the limitations and high risk of bias, promising results and cases with long-term survival with this approach have been described. Two ongoing clinical trials may answer the question that concerns us.
INTRODUCTION

Renal cell carcinoma (RCC) represents 2%-3% of all cancers[4]. We know that the last two decades there has been 2% increase per year in its incidence worldwide[5].

According to largest published series, approximately 20%-30% of patients with renal cell carcinoma present metastasis at time of diagnosis. Besides, another 20%-40% of patients with localized disease who have had a surgical treatment, either partial or radical nephrectomy, will have progression during follow-up[3].

The most frequently affected organs are lungs, lymph nodes, liver and bone[4]. Nowadays, there are six targeted therapies approved for mRCC treatment. These new agents have completely changed the treatment and prognostic of patients with mRCC, but the cure is rare with medical treatment alone. Metastasectomy when feasible remains a curative option in some patients[5].

These are some of the reasons why metastatic renal cell carcinoma (mRCC) is a challenging disease. The present review aims to clarify if there is an evidence to support combination of metastasectomy and adjuvant systemic targeted therapy in mRCC.

LITERATURE STUDY

We have made a search in Pubmed database, using the key words: "renal cell carcinoma", "metastatic renal cell carcinoma", "renal cell carcinoma metastasis", "metastasectomy", "neoadjuvant treatment", "adjuvant treatment", "local treatment"; "surgery"; in all languages and no date restrictions.

We included in the review all the studies that underwent the inclusion criteria: surgical treatment of metastatic renal cell carcinoma (yes/no), with emphasis on those that focused on neoadjuvant/adjuvant systemic therapy and metastasectomy.

RESULTS

Epidemiology of mRCC treated with metastasectomy

As mentioned above, around 20%-30% of patients with RCC have metastases when diagnosed, and 20%-40% of those with localized advanced disease will progress to metastatic disease.

The most commonly affected organ in mRCC is the lungs. Lymph nodes, liver, bone, adrenal glands and brain are other typical sites; but there are reported metastases in rare organs, like pancreas, skin, bladder; etc.

In a recent publication, the distribution according to different organs was: 45.2% in lungs, 29.5% in bone, 21.8% in lymph nodes and 20.3% in liver. It was observed that in patients with multiple metastatic sites, 16% and 49%, brain and bone were affected, respectively[6].

Without treatment, survival of RCC is lower than 10% at 5 years[7].

Other specific characteristic of RCC is the existence of documented late metastases (> 20 years from the primary diagnosis).

The first evidence of long survival after resection of a solitary lung lesion was published in 1939[8]. Since then, several retrospective series have confirmed the effectiveness of metastasectomy. However, there are no randomized or prospective studies available.

Some authors have reported 37.2%-42% 5-year survival rates in cases of mRCC with complete resection, in observational studies[9,10].

The best response has been found in resection of solitary lung metastases, with 56% 5-year survival compared to 28% for skin, 20% for visceral organs, 18% for peripheral bone, 13% brain and 9% for axial bone metastases[11].

General prognostic factors: Knowledge of prognostic factors is important for a correct selection of patients candidates to surgery.

A retrospective study of 278 cases treated with nephrectomy and a solitary metastasis treated with surgery found that the factors associated with favourable outcome were: solitary site and single metastasis, complete resection, a long disease-free interval and metachronous presentation[12].

In a large series of clear cell mRCC from de Mayo Clinic (Rochester, MN, United States) of 727 cases, prognostic factors of poor survival were: constitutional symptoms at nephrectomy, metastases to the bone or liver, multiple metastases, metastases at time of nephrectomy or in the 2 year thereafter, caval thrombus, Fuhrman grade 4 and coagulative tumour necrosis. In this study, complete resection of metastatic sites improved survival significantly[13].

Eggener et al[14] have published that in mRCC patients, the risk score classification according to Motzer classical factors and metastasectomy were independent factors of good outcome. The best survival was observed in patients with favourable risk and metastasectomy (71% 5-year survival) compared to that with high risk, with no survival at 5 years, independently of metastasectomy.

Recently, Tosco et al[15] have published a predictive model based on the following independent prognostic factors: primary tumour T stage ≥ 3, primary tumour Fuhrman grade ≥ 3, nonpulmonary metastases, disease-free interval ≤ 12 mo and multiorgan metastases. The Leuven-Udine (LU) prognostic groups are: (1) Group A (0-1 risk factors) with 5-year cancer specific survival (CSS) of 83.1%; (2) Group B (2 risk factors) with 5-year CSS of 56.4%; (3) Group C (3 risk factors) with 5-year CSS of 32.6%; and (4) Grupo D (4-5 risk factors) with 5-year CSS of 0%.

Another multiinstitutional study of 556 patients with mRCC who underwent metastasectomy in 48 Japanese hospitals found four adverse prognostic factors: incomplete resection of metastases, brain metastases, C-reactive protein > 1.0 mg/dL and high grade[16].
In conclusion, the prognostic factors of poor survival in patients with mRCC treated with metastasectomy are: (1) Primary tumour T stage ≥ 3; (2) Primary tumour Fuhrman grade ≥ 3 or high grade according to Japanese classification (nuclei of tumour cells larger than nuclei of normal tubular cells); (3) Nonpulmonary metastases; (4) Disease-free interval ≤ 12 mo; (5) Multiorgan metastases; (6) Incomplete resection of metastases; (7) Brain metastases; (8) C-reactive protein > 1.0 mg/dL; and (9) Motzer Classification risk score for mRCC (MSKCC risk score).

There are studies that evaluate the role of meta-
chronous multiple metastasectomies.

In a retrospective series of 99 cases surgically treated, Bone metastases are often symptomatic. The indications for surgical treatment are prolongation of OS and high risk, with different median OS (90, 31 and 14 mo respectively): (1) Munich score for mRCC (MSKCC risk score). In a large series of M.D. Anderson Cancer Center of 295 patients with 368 metastases treated, the OS rates were: 47% 1st year, 30% 2nd year and 11% 5th year. Patients with solitary metastasis showed better results, with a 5-year OS of 35%.

Patients with liver metastases have a poor prognosis due to that only 5% of the cases have a solitary meta-
chronous lesion. A series of 31 cases showed that negative resection-
margin was an independent prognostic factor in multi-
ivariate analysis. The 5-year OS was 38.9%

The largest retrospective series (88 patients with only liver metastases) found that those patients with synchronous metastases and a high grade RCC did not show benefit from surgery. The morbidity was 20.1%

Most of the cases of brain metastases (80%) are diagnosed by symptoms. Without treatment the prognosis is poor, with a survival of less of a few months. Treatment options are surgery and stereotactic radiosurgery.

In a series of 50 cases, resection of lung metastases and supratentorial (vs infratentorial) localization were good prognostic factors. Adjuvant radiotherapy showed no survival advantage.

A series of 69 cases published in 2003, with 146 lesions treated with radiosurgery achieved good local control. OS was 6 mo from treatment. Age, neurologic status and radiosurgery dose had an impact in OS.

A study of 46 cases with 99 brain lesions treated with radiosurgery achieved local control in 84.7% of patients. Median OS was 10 mo, but reached 18 mo when > 75% volume decrease.

There have been reported 411 patients with pancreatic metastases of RCC in 170 publications. Of 411 cases, 321 were surgically treated; with 65.3% of solitary lesions in surgery group. The 5-year OS was 72.6%, and disease specific survival was 57%. In-hospital mortality was 2.8%, 35.8% of patients underwent pancreaticoduodenectomy and 19.9% total pancreatectomy.

There are reports of RCC metastases in other organs, like adrenal, bladder, vagina, thyroid gland, paranasal sinuses. These publications are case reports and no clear prognosis knowledge can be made.

The panel of European Association of Urology Guidelines has made a systematic review in accordance with Cochrane review methodology. They concluded that all the studies were retrospective with a high risk of bias, but with the exception of brain and possibly bone metastases, surgery remains to be by default the best treatment for most sites.
In the last actualization of the Guidelines, the conclusion is that “no general recommendations can be made and the decision of metastasectomy has to be taken for each site, and on a case-by-case basis: performance status, risk profiles, patient preference and alternative techniques must be considered”.

Rationale of multimode therapy in mRCC
mRCC is a complex entity that can be treated with cytokine treatment, sequential targeted therapies and metastasectomy.

The correct moment and sequence of each treatment is not clear; but we have some evidence that combination of surgery and systemic therapies can achieved excellent outcomes.

Cytoreductive nephrectomy: It is known that nephrectomy is curative if surgery can excise all tumour deposits.

In a metaanalysis of two randomized trials comparing immunotherapy only vs nephrectomy and immunotherapy, a long-term survival was reported in cases treated with nephrectomy and immunotherapy in patients with good performance status[38].

In a retrospective study[39], the previous advantage of cytoreductive nephrectomy was confirmed in patients treated with vascular endothelial growth factor-targeted therapy (VEGF-targeted therapy).

However, the value of cytoreductive nephrectomy followed by VEGF-targeted therapy has to be confirmed by ongoing trials.

Adjuvant therapy after nephrectomy in localized RCC: Adjuvant tumour vaccination might improve duration of PFS in patients with T3 RCC, but has not effect in OS. Adjuvant therapy with cytokines does not improve survival[40,41].

There are several ongoing phase III trials of adjuvant sunitinib, sorafenib, pazopanib, axitinib and everolimus.

Presurgical treatment for locally advanced RCC:
Neoadjuvant treatment could be used with the following objectives: (1) Decrease tumour size and facilitate surgery; (2) Allow the performance of nephronsparing surgery; (3) Improve survival acting against micro-metastases; (4) Reduce morbidity of surgery by decreasing size and vascularisation of tumour; (5) Knowledge of response to systemic therapy before surgery; and (6) Future research.

Targeted therapies have been used in neoadjuvant/ preoperative settings in cases of locally advanced RCC (huge tumours, cases with large nodes near hilium and inferior vena cava thrombus) and in cases of T2 RCC with the aim to perform a nephronsparing procedure.

Sunitinib, sorafenib, axitinib, everolimus and temsirolimus are the 5 neoadjuvant therapies that have been used for locally advanced RCC treatment and before nephronsparing surgery.

First evidence of radiological downstaging effect of kinase inhibitors was reported in phase 2 and 3 trials[42,43].

In 2009, a complete histologic remission after sunitinib neoadjuvant therapy was reported in a case of T3b renal cell carcinoma[44].

The response of renal tumours to targeted therapies has been reported in small retrospective series and case reports. The most important series are summarized in Table 1[45-54].

Powles et al[55] reported that in cases of mRCC treated with sunitinib prior to nephrectomy, progression prior to planned nephrectomy, high Fuhrman grade and MSKCC poor risk at diagnosis were independent prognostic factors.

Another group made a systematic review[56] and concluded that downsizing of primary tumours with neoadjuvant sunitinib or sorafenib was related to size at presentation, being the major effect in tumours sized 5 to 7 cm.

Due to the high rate of surgical complications in IVC thrombus RCC, reduction of size of tumour thrombus with neoadjuvant sunitinib, sorafenib, axitinib and temsirolimus has been reported.

The majority of the published information are case reports[57-60]. The largest series reported 25 patients, 7 of which had level 3 or 4 IVC thrombus. 12% reduced thrombus size (only after sunitinib treatment), but the reduction (Median 1.5 cm) didn’t have any impact on the surgery approach[61].

In 2010, Bex et al[62] reported two cases of IVC thrombi progression during neoadjuvant treatment with sunitinib.

Recently, Bigot et al[63], in a retrospective series of 14 cases treated with sunitinib or sorafenib, found that 43% of the patients had a measurable decrease while 14% had an increase in thrombus size. Only 1 case downstaged thrombus level. However, 50% of renal tumours experienced a significant reduction in size. They concluded that neoadjuvant therapy had limited impact on IVC thrombi RCC surgical management.

In conclusion, the response of primary tumour to targeted therapies is unpredictable, although 42%-100% cases show tumour shrinkage. The major effect reported was after sunitinib treatment and in smaller tumours (5 to 7 cm). Morbidity of these novel agents should be taken into account.

There are a few studies focused on the concept of neoadjuvant systemic therapy prior to metastasectomy.

Rini et al[64] described 2 patients with long-term response who were treated with adjuvant sunitinib and metastasectomy.

Thomas et al[65] reported 19 cases treated with surgery after targeted therapy, 3 of them with metastasectomy with partial response and good outcome.

In 2009, Daliani et al[66] reported 38 patients with mRCC, treated with targeted therapy and a partial response/stable disease who underwent metastasectomy
(84% only one organ site). Ten percent of patients suffered complications. Twenty-one percent of patients were remained of disease. Absence of histological viable tumour in metastasectomy specimens and lung metastases had an OS of 5.6 years compared with those who did not (1.4 years).

In 2012, Karam et al. reported 22 cases with mRCC who received neoadjuvant treatment prior to metastasectomy with one of the following targeted therapies: sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, Interleukin-2, ABT-510. 4 cases had multiple metastases and 6 suffered complications. At 109 weeks, only one patient died from RCC. 11 (50%) cases experimented no recurrence.

Another study of 2012 reported 11 patients treated surgically after ≥ 3 mo of stable partial remission with sunitinib, bevacizumab or sunitinib plus temsirolimus. Seven cases had node retroperitoneal disease. Only 1 complication was reported. 5 cases showed no recurrence after a median follow-up of 12 mo.

In a series of 143 patients with mRCC treated with systemic therapy, those who were treated with metastasectomy too (n = 42) had a better OS (18.8 mo vs 15 mo, P = 0.07). A group of Japanese authors described two cases of large adrenal metastasates with liver and pancreas invasion that were successfully treated with sunitinib prior to surgery with a good outcome.

A case report of a man with mRCC who was treated with surgery plus immunotherapy was 56.1 mo vs 21.3 mo in the only-surgery group. But when patients were stratified by time of metastases, no differences were found. In multivariate analysis only multiplicity of metastases and metastases sites were independent prognostic factors. Authors concluded that metastasectomy plus adjuvant immunotherapy did not render a higher overall survival.

Johannsen et al. studied the discontinuation of targeted therapy after complete response to sunitinib. 12 cases were identified, 50% (6 cases) treated with sunitinib and consolidative metastasectomy (lungs, bone, skin and thyroid). No adjuvant treatment was prescribed. Only 5 of 11 patients experienced recurrence, with effective rescue after targeted therapy in all cases. In a recent actualization of the series, with 36 cases, 33.3% remained free of recurrence during follow-up. Factors that correlate with outcome, including metastasectomy, could not be identified.

### Adjuvant targeted therapy after metastasectomy

It is known that neoadjuvant targeted therapy can be related with surgical complications, as mentioned above. Systemic treatment can obliterate normal tissues planes and make surgery more difficult and risky. A recent review concluded that no general recommendations can be made about use of targeted therapy in preoperatory setting.

Based on evidence of effectiveness of multimodal treatment in different moments of mRCC, we try to answer the question of the title: Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

In 2007, Kwak et al. reported 93 patients with mRCC treated with metastasectomy with or without adjuvant immunotherapy. Overall survival of group treated with surgery plus immunotherapy was 56.1 mo vs 21.3 mo in the only-surgery group. But when patients were stratified by time of metastases, no differences were found. In multivariate analysis only multiplicity of metastases and metastases sites were independent prognostic factors. Authors concluded that metastasectomy plus adjuvant immunotherapy did not render a higher overall survival.

Jacobsohn et al. reported no effect of adjuvant Interferon after lung metastasectomy.

Since then, some case reports suggest that adjuvant targeted therapy could be effective after metastasectomy.

In 2010, a study with 88 cases with liver metastases of RCC was published. Sixty-eight were treated with surgery and 78% of cases received adjuvant treatment in both groups (metastasectomy yes/no). The 5-year overall survival rate after metastasectomy was 62.2% with a median survival of 142 mo compared with 29.3% and 27 mo in the control group. High-grade RCC as well as patients with synchronous metastases did not benefit from surgery.

A case report of a man with mRCC who was treated with metastasectomy for multiple organs deposits and adjuvant pazopanib showed 8-year survival.

In 2012, Gardini et al. described 8 cases of pancreatic metastases of RCC treated surgically and with adjuvant therapy (mostly immunotherapy), with disease free survival after 3 years of 30%.

In most of previous papers of neoadjuvant treatment after metastasectomy, adjuvant systemic therapies

### Table 1 Main series of neoadjuvant therapy in locally advanced renal cell carcinoma

| Ref. | No. | Therapy | Median size | % median reduction | Partial response | < 30% shrinkage | % cases tumour shrinkage | Toxicity Grade |
|------|-----|---------|-------------|-------------------|-----------------|----------------|--------------------------|---------------|
| Thomas et al. | 19 | Sunitinib | 10.5 | 24% | 3 | 8 | 42% | 37% |
| Helleththal et al. | 20 | Sunitinib | 7 | 27.90% | 2 | 15 | 85% | 30% |
| Silberstein et al. | 14 | Sunitinib | 7 | 21% | 4 | 10 | 100% | - |
| Kondo et al. | 9 | Sunitinib/sorafenib | - | 9%-30% | 3 | 6 | 100% | 2 major surgery complications |
| Rini et al. | 28 | Sunitinib | - | 22% | - | - | - | - |
| Powles et al. | 52 | Sunitinib | - | - | - | - | 73% | - |
| Bex et al. | 10 | Sunitinib | - | 50% | - | - | 60% | - |
| Kats-Elguergu et al. | 10 | Sorafenib | 7.5 | 14% | - | - | - | - |
| Cowey et al. | 30 | Sorafenib | 8.7 | 9.60% | 2 | 23 | 80% | - |
| Karam et al. | 24 | Axitinib | - | 28.30% | 11 | - | 100% | 41.70% |
are also used. For instance, in Karam et al\cite{67} study, 9 of 22 patients received at least one adjuvant targeted therapy. Effect of this intervention in survival was not assessed. Daliani et al\cite{66} also gave consolidative adjuvant systemic therapy.

A study of 106 cases with mRCC and brain metastases used combination of targeted therapy and local treatments. The patients were treated with sunitinib (n = 77), sorafenib (n = 23), bevacizumab (n = 5), and temsirolimus (n = 1). Local disease treatment included whole brain radiotherapy (81%), stereotactic radiosurgery (25%), and neurosurgery (25%). On multivariable analysis, surgery or radiosurgery failed to demonstrate to increase OS\cite{80}.

Two ongoing clinical trials published in Pubmed are studying adjuvant therapy after metastasectomy: (1) RESORT protocol\cite{81}: a randomized, open-label, multicenter phase II study to evaluate efficacy of sorafenib in patients with mRCC after complete metastasectomy. One hundred and thirty-two patients will be randomized to receive sorafenib or best supportive care, with a follow-up of 36 mo; and (2) SMAT-AN 20/04 of the Working Group of Urological Oncology (AUO)\cite{82}: a prospective randomized multicenter phase II study on resection of lung metastases in clear cell carcinoma ± adjuvant sunitinib over 1 year.

CONCLUSION

mRCC is a challenging disease. Despite the new targeted therapies, complete remissions occur only in 1%-3% of the cases, and the most effective first-line treatment drugs have reached a ceiling in OS (ranging from 9 to 49 mo)\cite{5}.

Metastasectomy remains to be the only curative option in most patients with mRCC. Prognostic models for general\cite{15,16} and lung metastases\cite{86} have been recently published, so we have tools to classify patients in risk groups, allowing us to detect the cases with the higher risk of recurrence after metastasectomy.

Although sparse, there is some evidence of effectiveness of adjuvant targeted therapy before metastasectomy; but with an increase in surgical complications due to the effects of these new drugs in tissue healing.

In 2007, Jacobsohn et al\cite{77} concluded that metastasectomy plus adjuvant immunotherapy did not result in a higher overall survival and published a paper titled: “No role of adjuvant therapy after complete metastasectomy in metastatic renal cell carcinoma?”

Since then, mRCC treatment has dramatically changed after the approval of new drugs. We have aimed to answer the question: Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma? As far as we know, evidence is low and it’s based in case reports and small series of patients treated with adjuvant drugs after neoadjuvant therapy plus metastasectomy in cases of partial response to initial systemic treatment. Despite the limitations and high risk of bias, promising results and cases with long-term survival with this approach have been described\cite{32,66,78-80}.

Two ongoing clinical trials\cite{81,82} may answer the question that concerns us. While we wait for the results, the recommendations of European Association of Urology Guidelines\cite{37} are a rationale tool: “the decision of metastasectomy has to be taken for each site, and on a case-by-case basis: Performance status, risk profiles, patient preference and alternative techniques must be considered”. From our point of view, adjuvant targeted therapy after metastasectomy combined or not with neoadjuvant treatment could be an effective multimodal approach in the future.

REFERENCES

1 European Network of Cancer Registries: Eurocem version 4.0. European incidence database V2.3, 730 entity dictionary (2001). Lyon: ENCR, 2001
2 Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg 2004; 93: 88-96 [PMID: 15285559]
3 Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173: 1853-1862 [PMID: 15879764 DOI: 10.1097/01.ju.0000165693.68449.e3]
4 Rautu M, Bono P, Taari K. Resection of renal cell cancer metastases: where do we stand in 2008? Eur Urol Suppl 2008; 7: 436-442 [DOI: 10.1016/j.eusurop.2008.01.005]
5 Bex A. Integrating metastasectomy and stereotaxic radiosurgery in the treatment of metastatic renal cell carcinoma. EJC Supplements 2013; 2: 192-203 [DOI: 10.1016/j.ejcsup.2013.07.017]
6 Bianchi M, Sun M, Jeldres C, Shiralt SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Porrette P, Menon M, Montorsi F, Karakiewicz P. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012; 23: 973-980 [PMID: 21909909 DOI: 10.1093/annonc/mdr362]
7 Ljungberg B. Prognostic factors in renal cell carcinoma. Scand J Surg 2004; 93: 118-125 [PMID: 15285563]
8 Barney JD, Churchill J. Adenocarcinoma of the kidney with metastases to the lung. J Urol 1939; 42: 271
9 Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002; 73: 1082-1087 [PMID: 11962645 DOI: 10.1016/S0003-4975(01)03602-5]
10 Assouad J, Petkova B, Berna P, Djouad A, Foucault C, Riquet M. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 2007; 84: 1114-1120 [PMID: 17889586 DOI: 10.1016/j.athoracsur.2007.04.118]
11 Swanson DA. Surgery for metastases of renal cell carcinoma. Scand J Surg 2004; 93: 150-155 [PMID: 15285568]
12 Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-2266 [PMID: 9626299]
13 Leibovich BC, Cheville JC, Lohe CM, Zincke H, Frank I, Kwon ED, Merchans JR, Blute ML. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174: 1759-1763; discussion 1763 [PMID: 16217278 DOI: 10.1097/01.ju.0000177487.64651.3a]
14 Eggener SE, Yossepowitch O, Kundra S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 2008; 180: 873-878; discussion 878 [PMID: 18635225 DOI: 10.1016/j.juro.2008.05.006]
F, Bernhard JC, Ravaud A, Ballanger P. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. *Eur Urol* 2009; 55: 1477-1480 [PMID: 1910517 DOI: 10.1016/j.eururo.2008.12.031]

45 Thomas AA, Bini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. *J Urol* 2009; 181: 518-523; discussion 523 [PMID: 19100579 DOI: 10.1016/j.juro.2008.10.001]

46 Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, Teh BT, Kim HL. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. *J Urol* 2010; 184: 859-864 [PMID: 20643461 DOI: 10.1016/j.juro.2010.05.041]

47 Silberstein JL, Millard F, Mehrzian R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. *BJU Int* 2010; 106: 1270-1276 [PMID: 20394613 DOI: 10.1111/j.1464-1097.2010.09535.x]

48 Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Ishikawa T, Nakano M, Tanabe K. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. *Jpn J Clin Oncol* 2010; 40: 1173-1179 [PMID: 20968917 DOI: 10.1016/j.jjco.2010.04.010]

49 Rini BI, Garcia J, Elson P, Nakayama T, Nakagawa N, Yao M, Kubota Y. Presurgical downstaging of venous caval tumor thrombus in advanced clear cell renal cell carcinoma using tensirometry. *Int J Urol* 2013; 20: 637-639 [PMID: 23186017 DOI: 10.1111/iju.12012]

50 Di Silverio F, Sciarra A, Parente U, Andrea A, Von Heland M, Makiyama K, Tatenuma T, Sakata R, Yamanaka H, Hashimoto Y, Kobayashi H, Iizuka J, Nishikawa T. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. *Urol Int* 2008; 80: 451-453 [PMID: 18587261 DOI: 10.1055/s-0031-1237028]

51 Sassa N, Kato M, Funahashi Y, Maeda M, Inoue S, Gotoh M. Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma. *Jpn J Clin Oncol* 2014; 44: 370-373 [PMID: 24571808 DOI: 10.1093/jjco/hyt14]

52 Cost NG, Delacroix SE, Sheep JF, Smith JP, Youssef RF, Champion BR, Karam JA, Culp S, Abel EJ, Brugallaos J, Raj GV, Sagalowsky AJ, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena cava tumor thrombus. *Eur Urol* 2011; 59: 912-918 [PMID: 21367518 DOI: 10.1016/j.eururo.2011.02.032]

53 Bex A, van der Veldt AA, Blank C, Meijerink MR, Boven E, Haenens JB. Progression of a caudal vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. *Acta Oncol* 2010; 49: 520-523 [PMID: 20105587 DOI: 10.3109/02841075.2010.549692 DOI: 10.1016/j.eururo.2011.02.032]

54 Bigot P, Fardoun T, Bernhard JC, Xylinas E, Berger J, Roupert M, Beauval JB, Gabrielle S, Lebdai S, Ammi M, Baumert H, Escudier B, Grenier N, Hétet JF, Long JA, Papirol P, Rioux-Leclercq N, Soulé M, Azzouzi AR, Bensalah K, Patard JJ. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? *World J Urol* 2014; 32: 109-114 [PMID: 23624719 DOI: 10.1007/s00345-013-1086-1]

55 Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. *Clin Genitourin Cancer* 2006; 5: 232-234 [PMID: 17239278 DOI: 10.3816/CJC.2006.n.042]

56 Thomas AA, Rini BI, Stephenson AJ, Garcia J, Fargnroy A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC. Surgical resection of renal cell carcinoma after targeted therapy. *J Urol* 2009; 182: 881-886 [PMID: 19661232 DOI: 10.1016/j.juro.2009.05.014]

57 Dalani DD, Tannir NM, Paeandreau CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. *BJU Int* 2009; 104: 456-460 [PMID: 19338544 DOI: 10.1111/j.1464-410X.2009.08490.x]

58 Karam JA, Rini BI, Varella L, Garcia J, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. *J Clin Oncol* 2011; 29: 439-444 [PMID: 21675189 DOI: 10.1200/jco.2010.09.086]

59 Firek P, Richter S, Jaekel J, Brehmer B, Heidereich A. [Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors]. *Urologe A* 2012; 51: 398-402 [PMID: 22215533 DOI: 10.1007/s00120-011-2762-9]

60 De Lichtenberg TH, Herrnng GM, Rorht M, Heijer Larsen MJ, Mansourvar Z, Holm ML, Scheike T. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre. *Scand J Urol* 2014; 48: 379-386 [PMID: 24521185 DOI: 10.3109/1013876550]
metastasis from renal cell carcinoma: a case report. Hinyokika Kiyo 2013; 59: 573-577 [PMID: 24113755]

71 Hamada A, Sunada T, Kato K, Sawada A, Kawanishi H, Okumura K. [A case of adrenal metastasectomy in renal cell carcinoma after neoadjuvant therapy with sunitinib]. Hinyokika Kiyo 2014; 60: 79-82 [PMID: 24755818]

72 Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeppers C, Rief M, Rogalla P, Miller K, Grünwald V. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009; 55: 1430-1438 [PMID: 18950936 DOI: 10.1016/j.eururo.2008]

73 Johannsen M, Staehler M, Otthmann CH, Flörcken A, Schmittel A, Otto T, Bex A, Heim P, Miller K, Weikert S, Grünwald V. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann Oncol 2011; 22: 657-663 [PMID: 20870911 DOI: 10.1093/annonc/mdq437]

74 Shuch B, Riggs SB, LaRochelle JC, Kabbainavar FF, Avakian R, Pannack AJ, Patard JJ, Belldegrun AS. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008; 102: 692-696 [PMID: 18410444 DOI: 10.1111/j.1464-410X.2008.07660.x]

75 Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010; 11: 373-382 [PMID: 20171141 DOI: 10.1016/S1470-2045(09)70341-9]

76 Kwak C, Park YH, Jeong CW, Lee SE, Ku JH. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma? Urol Oncol 2007; 25: 310-316 [PMID: 17628297 DOI: 10.1016/j.urolonc.2006.08.022]

77 Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol 2006; 33: 576-582 [PMID: 16154886 DOI: 10.1053/j.seminoncol.2006.06.005]

78 Joshi S, Eldefrawy A, Ciancio G. 8-year survival in a patient with several recurrences of renal cell carcinoma after radical nephrectomy. Cent European J Urol 2012; 65: 242-243 [PMID: 24578974 DOI: 10.5173/ceju.2012.04.art16]

79 Gardini A, Morgagni P, Milandri C, Riccobon A, Ridolfi R, La Barba C, Saragoni L, Amadori D, Garcea D. Pancreatic resection for metastases from renal cancer: long term outcome after surgery and immunotherapy approach - single center experience. Hepatogastroenterology 2012; 59: 687-690 [PMID: 22469709]

80 Vickers MM, Al-Harbi H, Choueiri TK, Kollmannsberger C, North S, MacKenzie M, Knox JJ, Rini BI, Heng DLY. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013; 11: 311-315 [PMID: 23684422 DOI: 10.1016/j.clgc.2013.04.012]

81 Procopio G, Verzoni E, Biondani P, Grassi P, Testa I, Garanzini E, de Braud F. Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases. Tumori 2014; 100: e28-e30 [PMID: 24675507 DOI: 10.1700/1430.15834]

82 Rexer H. [Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO)]. Urologe A 2012; 51: 252-253 [PMID: 22331073 DOI: 10.1007/s00120-012-2809-6]

P- Reviewer: Apostolou KG, Hirahara N  S- Editor: TianYL  L- Editor: A  E- Editor: LuYJ
